Cerebrolysin dosage: the regimens trials actually used

The honest way to talk about Cerebrolysin dosing is to say up front what it is not: it is not a prescription with an approved label, because Cerebrolysin is not FDA-approved in the United States and is not registered across most of the EU. So “the dose” here means the dose researchers infused into patients in trials — nothing more. For the separate and more important question of whether those doses actually help, read our Cerebrolysin evidence monograph first; this page only describes how it was given.

How it's administered: by injection or infusion, not a pill

Cerebrolysin is a liquid peptide preparation given parenterally — there is no oral form. In practice that means either an intramuscular (IM) injection for smaller volumes or, for the larger doses used in stroke, a slow intravenous (IV) infusion administered by a clinician.^[3] That route is central to the honesty of this topic: unlike an oral peptide you might mismeasure at home, this is a drug designed to be diluted and infused under medical supervision, which is exactly how every trial below delivered it.

The stroke regimen: 30 mL/day, once daily, IV

The two largest randomized stroke trials converged on the same daily dose. In the CASTA trial — 1,070 patients with acute ischemic stroke across Asia — patients received 30 mL of Cerebrolysin daily, as an intravenous infusion, for 10 days, started within 12 hours of symptom onset and given on top of aspirin.^[3] In CARS, an early-rehabilitation trial, the daily dose was identical — 30 mL/day, once daily — but the course ran longer, for 21 days, begun 24 to 72 hours after the stroke and paired with a standardized rehabilitation program.^[2] So the recurring trial number is 30 mL once daily; what varied was the length of the course, not the size of each dose.

It's a course, sometimes cycled — not an ongoing dose

The structural feature that separates Cerebrolysin from a daily supplement is that it is given as a defined course: a fixed run of daily infusions — on the order of 10 to 21 days in the stroke trials above — after which dosing stops.^[2][3] In the chronic settings where it is marketed abroad, such as vascular dementia, those courses are typically repeated as intermittent cycles rather than taken continuously; the Cochrane review of vascular dementia catalogues exactly this kind of small, mostly regional, course-based trial — and grades the resulting evidence as very low quality.^[4] The takeaway for dosing is that even where Cerebrolysin is used, it is dosed in bounded cycles under supervision, not swallowed indefinitely.

Why more is not the answer

A natural instinct with any weak-signal drug is to reach for a higher or longer dose. The pooled evidence argues against that. The Cochrane review of Cerebrolysin for acute ischaemic stroke concluded, with moderate-certainty evidence, that it probably has no beneficial effect on death, and it flagged a possible increase in non-fatal serious adverse events.^[1] When the best synthesis of the trial data shows no benefit at the studied dose and raises a safety question, escalating the dose is not a rational workaround — it is added risk without evidence of added benefit. The same skeptical framing applies to the injectable peptide-nootropics Cerebrolysin is often grouped with; see how thin the dosing evidence is for Semax and Selank, which are likewise dosed from convention rather than from robust trials.

The honest bottom line

Reduced to what the evidence actually documents: Cerebrolysin was given as 30 mL once daily by intravenous infusion, over courses of roughly 10 days (CASTA) to 21 days (CARS), sometimes repeated in cycles in chronic use.^[2][3] But there is no approved dose, the pooled stroke data show no benefit on death and a hint of added harm at that very regimen, and the whole thing depends on clinician-controlled parenteral administration that an imported vial cannot replicate.^[1] The dose is the easy part to write down; the reasons it is not a do-it-yourself protocol are the part that matters. For the full efficacy and safety picture, return to the Cerebrolysin evidence review.